drugset / Trial / NCT05438303

Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers

NCT05438303 ↗

Phase 1 Completed 59 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelOther

Summary

This study will be a fixed sequence drug-drug interaction study in healthy postmenopausal females, conducted at multiple study sites

Timeline

Start
2022-06-13
Primary completion
2022-12-13
Completion
2022-12-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Camizestrant Other / unclassified — Oral
Subject Celecoxib Other / unclassified — Oral
Subject Dabigatran etexilate Unknown — Oral
Subject Midazolam Small molecule — Oral
Subject Omeprazole Other / unclassified — Oral

Indications

No indication recorded.